LAVAL, QC, Sept. 19 /CNW/ - Warnex Inc. (TSX: WNX) today announced that
its Medical Laboratories division has signed an agreement with Organon Canada
Ltd., a renowned biopharmaceutical company based in Scarborough, Ontario, to
provide bioavailable testosterone testing to their customers across Canada.
"We are pleased to collaborate with Organon, a leader in the development
of pharmaceutical products", said Mark Busgang, President and CEO of Warnex.
"Warnex uses a unique and very specific method for the detection of
bioavailable testosterone. This agreement with Organon validates Warnex's
strategy to focus on specialized medical testing aimed at niche markets."
The bioavailable testosterone test is a diagnostic test recommended for
male patients in evaluating a condition known as andropause. Andropause is
caused by a decrease in hormone with age, which plays a direct role in various
physiological changes, including muscle strength, bone density and body
composition. Warnex's test measures the amount of bioavailable testosterone,
the biologically active form of testosterone, in human serum.
Warnex (www.warnex.ca) is a life sciences company devoted to protecting
public health by providing laboratory services to the pharmaceutical and
healthcare sectors. Warnex's analytical services division provides
pharmaceutical and biotechnology companies with a variety of quality control
services, including traditional chemistry, chromatography, microbiology,
method development and validation, and stability studies. Warnex's
bioanalytical services division specializes in bioequivalence and
bioavailability studies for clinical trials. Warnex's medical laboratories
division focuses on genetic and biochemical testing for the healthcare
industry and has extensive expertise in genetic testing for human
identification, molecular diagnostics, and pharmacogenetics.
Organon creates, manufactures and markets innovative prescription
medicines that improve the health and quality of human life. Through a
combination of innovation and business partnerships, Organon seeks to leverage
its position as a leading biopharmaceutical company in each of its core
therapeutic fields: fertility, gynecology and selected areas of anesthesia. It
has extensive expertise in neuroscience and a rich and focused R&D program.
Research areas also include immunology and specific areas of oncology. Organon
products are distributed in over 100 countries worldwide, of which more than
50 have an Organon subsidiary. Organon is the human healthcare business unit
of Akzo Nobel.
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this news release are forward-looking and
are subject to numerous risks and uncertainties, known and unknown. For
information identifying known risks and uncertainties, relating to the
integration of acquisitions, laboratory facilities, suppliers, key employees,
key customers and business partners, financial resources and credit risk,
government regulations, foreign currency risk, volatility of share price,
strategic options for the Company, and other important factors that could
cause actual results to differ materially from those anticipated in the
forward-looking statements, please refer to the heading Risks and
Uncertainties in the Management's Discussion and Analysis for the second
quarter ended June 30, 2007, which can be found at www.sedar.com.
Consequently, actual results may differ materially from the anticipated
results expressed in these forward-looking statements.
For further information:
For further information: Mark J. Busgang, President & CEO, Warnex Inc.,
Tel: (450) 663-6724 x.310, email@example.com